AI is spitting out more potential drugs than ever. This startup wants to figure out which ones matter.
The Rising Challenge in Drug Discovery
Artificial intelligence has revolutionized protein structure prediction, opening a floodgate of potential drug candidates. However, the real challenge lies in thoroughly analyzing these candidates to identify the most promising ones for development and mass production.
10x Science: Streamlining Drug Characterization
Founded in December 2025, 10x Science aims to address this bottleneck in pharmaceutical research. Fresh from a $4.8 million seed round led by Initialized Capital, with investments from Y Combinator and others, the company is led by David Roberts, Andrew Reiter, and Vishnu Tejus – scientists with deep expertise in biology and AI.
The core issue they tackle: while AI supplies numerous drug possibilities, it’s the next step—characterization—where progress stalls. Every candidate must be scrutinized and measured to understand its molecular makeup, a time-consuming and technically demanding task.
How 10x Science’s Platform Works
10x Science enhances mass spectrometry analysis—a precise method for determining molecular structure—by combining advanced chemical and biological algorithms with AI. Their platform streamlines the interpretation of mass spec data, making results both faster and thoroughly traceable for regulatory needs.
Feedback from early users, like Matthew Crawford of Rilas Technologies, underlines the platform’s ability to explain its findings, automate data search, and adapt to various molecules, all while maintaining scientific rigor.
Impact and Future Plans
10x Science is already collaborating with major pharma companies and academic institutions. Their new funding will support hiring and continuous improvement of the platform, aiming to expand its capabilities and user base.
Ultimately, the founders envision their technology as a new approach to understanding biological systems, making advanced molecular intelligence accessible to more researchers. By offering a SaaS solution, they provide value independently of any single drug’s commercial success.
For more details, read the original article by Tim Fernholz on TechCrunch.
